

Kaixin Zhou

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4670418/publications.pdf>

Version: 2024-02-01

29
papers

1,924
citations

361413

20
h-index

552781

26
g-index

31
all docs

31
docs citations

31
times ranked

3234
citing authors

#	ARTICLE	IF	CITATIONS
1	Common variants near ATM are associated with glycemic response to metformin in type 2 diabetes. <i>Nature Genetics</i> , 2011, 43, 117-120.	21.4	390
2	Pharmacogenetic meta-analysis of genome-wide association studies of LDL cholesterol response to statins. <i>Nature Communications</i> , 2014, 5, 5068.	12.8	216
3	Association of Organic Cation Transporter 1 With Intolerance to Metformin in Type 2 Diabetes: A GoDARTS Study. <i>Diabetes</i> , 2015, 64, 1786-1793.	0.6	188
4	Variation in the glucose transporter gene SLC2A2 is associated with glycemic response to metformin. <i>Nature Genetics</i> , 2016, 48, 1055-1059.	21.4	165
5	Reduced-Function <i>SLC22A1</i> Polymorphisms Encoding Organic Cation Transporter 1 and Glycemic Response to Metformin: A GoDARTS Study. <i>Diabetes</i> , 2009, 58, 1434-1439.	0.6	153
6	Heritability of variation in glycaemic response to metformin: a genome-wide complex trait analysis. <i>Lancet Diabetes and Endocrinology</i> , 2014, 2, 481-487.	11.4	101
7	Visit-to-Visit HbA1c Variability Is Associated With Cardiovascular Disease and Microvascular Complications in Patients With Newly Diagnosed Type 2 Diabetes. <i>Diabetes Care</i> , 2020, 43, 426-432.	8.6	85
8	Meta-analysis of up to 622,409 individuals identifies 40 novel smoking behaviour associated genetic loci. <i>Molecular Psychiatry</i> , 2020, 25, 2392-2409.	7.9	83
9	Clinical and Genetic Determinants of Progression of Type 2 Diabetes: A DIRECT Study. <i>Diabetes Care</i> , 2014, 37, 718-724.	8.6	59
10	<i>CYP2C8</i> and <i>SLCO1B1</i> Variants and Therapeutic Response to Thiazolidinediones in Patients With Type 2 Diabetes. <i>Diabetes Care</i> , 2016, 39, 1902-1908.	8.6	52
11	Acute kidney injury, plasma lactate concentrations and lactic acidosis in metformin users: A GoDarts study. <i>Diabetes, Obesity and Metabolism</i> , 2017, 19, 1579-1586.	4.4	49
12	Pharmacogenomics in diabetes mellitus: insights into drug action and drug discovery. <i>Nature Reviews Endocrinology</i> , 2016, 12, 337-346.	9.6	47
13	Variation in the Plasma Membrane Monoamine Transporter (PMAT) (Encoded by <i>SLC29A4</i>) and Organic Cation Transporter 1 (OCT1) (Encoded by <i>SLC22A1</i>) and Gastrointestinal Intolerance to Metformin in Type 2 Diabetes: An IMI DIRECT Study. <i>Diabetes Care</i> , 2019, 42, 1027-1033.	8.6	43
14	Effect of Serotonin Transporter 5-HTTLPR Polymorphism on Gastrointestinal Intolerance to Metformin: A GoDARTS Study. <i>Diabetes Care</i> , 2016, 39, 1896-1901.	8.6	41
15	Rates of glycaemic deterioration in a real-world population with type 2 diabetes. <i>Diabetologia</i> , 2018, 61, 607-615.	6.3	40
16	Genetic Variants in <i>CPA6</i> and <i>PRPF31</i> Are Associated With Variation in Response to Metformin in Individuals With Type 2 Diabetes. <i>Diabetes</i> , 2018, 67, 1428-1440.	0.6	32
17	Insights from Genome-Wide Association Studies of Drug Response. <i>Annual Review of Pharmacology and Toxicology</i> , 2013, 53, 299-310.	9.4	31
18	Association between Diabetes Complications and the Triglyceride-Glucose Index in Hospitalized Patients with Type 2 Diabetes. <i>Journal of Diabetes Research</i> , 2021, 2021, 1-6.	2.3	28

#	ARTICLE	IF	CITATIONS
19	Pathogenicity and Penetrance of Germline SDHA Variants in Pheochromocytoma and Paraganglioma (PPGL). <i>Journal of the Endocrine Society</i> , 2018, 2, 806-816.	0.2	25
20	Interaction between variants in the CYP2C9 and POR genes and the risk of sulfonylurea-induced hypoglycaemia: A GoDARTS Study. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 211-214.	4.4	24
21	Genome-Wide Meta-analysis Identifies Genetic Variants Associated With Glycemic Response to Sulfonylureas. <i>Diabetes Care</i> , 2021, 44, 2673-2682.	8.6	23
22	Pharmacogenetics in type 2 diabetes: influence on response to oral hypoglycemic agents. <i>Pharmacogenomics and Personalized Medicine</i> , 2016, 9, 17.	0.7	16
23	Utility of Population-Level DNA Sequence Data in the Diagnosis of Hereditary Endocrine Disease. <i>Journal of the Endocrine Society</i> , 2017, 1, 1507-1526.	0.2	15
24	mTORC2/RICTOR exerts differential levels of metabolic control in human embryonic, mesenchymal and neural stem cells. <i>Protein and Cell</i> , 2022, 13, 676-682.	11.0	6
25	Evidence-based prioritisation and enrichment of genes interacting with metformin in type 2 diabetes. <i>Diabetologia</i> , 2017, 60, 2231-2239.	6.3	4
26	<i>KCNQ1</i> variant rs163184 is a potential biomarker of glycemic response to exenatide. <i>Pharmacogenomics</i> , 2022, 23, 355-361.	1.3	4
27	Genome-Wide Meta-Analysis Identifies the Organic Anion-Transporting Polypeptide Gene <i>SLCO1B1</i> and Statins as Modifiers of Glycemic Response to Sulfonylureas. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
28	Scalable Dual-Fluorescence Assay for Functional Interpretation of HNF-4A Missense Variants. <i>Frontiers in Endocrinology</i> , 2022, 13, 812747.	3.5	0
29	Response to Comment on Dawed et al. Genome-Wide Meta-analysis Identifies Genetic Variants Associated With Glycemic Response to Sulfonylureas. <i>Diabetes Care</i> 2021;44:2673-2682. <i>Diabetes Care</i> , 2022, 45, e82-e83.	8.6	0